View Clovis Oncology's earnings history. CLOVIS ONCOLOGY, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for CLOVIS ONCOLOGY, INC. Stock | CLVS | Learn more. View insider buying and selling activity for Clovis Oncology or view top insider-selling stocks. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Signals & Forecast. (Add your “underperform” vote.). Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. and Principal Financial & Accounting Officer, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. CLVS Stock Forecast. Get daily stock ideas top-performing Wall Street analysts. CNN Sans™ & © 2016 Cable News Network. The average price target represents a 84.74% upside from the last price of $4.98. Clovis Oncology has received 50.57% “outperform” votes from our community. CLVS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Pinnacle Associates Ltd., and Vigilare Wealth Management. Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen. 57.83% of the stock of Clovis Oncology is held by institutions. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares. (Add your “outperform” vote. In the past three months, Clovis Oncology insiders have sold more of their company's stock than they have bought. This suggests a possible upside of 50.3% from the stock's current price. Learn everything you need to know about successful options trading with this three-part video course. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Identify stocks that meet your criteria using seven unique stock screeners. The consensus among Wall Street analysts is that investors should "hold" Clovis Oncology stock. ET by Barron's Clovis Oncology stock price … Export data to Excel for your own analysis. Clovis Oncology has received a consensus rating of Hold. Fundamental company data provided by Morningstar and Zacks Investment Research. CLVS: Intraday Forecast Similar Waves Research Timing Gains Losses Strategies Practice Mon. Find real-time CLVS - Clovis Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis. 6 Wall Street analysts have issued 12 month price targets for Clovis Oncology's stock. Given the current horizontal trend, you can expect Clovis Oncology stock with a 90% … The company provided earnings per share (EPS) guidance of for the period. Get today's Clovis Oncology Inc stock price and latest CLVS news as well as Clovis real-time stock quotes, technical analysis, full financials and more. Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Thursday, November, 5th. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. View our earnings forecast for Clovis Oncology. Clovis Oncology has a market capitalization of $811.65 million and generates $143.01 million in revenue each year. View institutional ownership trends for Clovis Oncology. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. Clovis Oncology is a small oncology company from the US. CLVS stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Pacer Advisors Inc.. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen. The biopharmaceutical company reported ($0.89) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.12. Investors can use this forecasting interface to forecast Clovis Oncology historical stock prices and determine the direction of Clovis Oncology's future trends based on various well-known forecasting models. The one-year Clovis Oncology Inc. stock forecast points to a potential downside of -7.78. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Never miss a profitable trade. MarketBeat just released five new trading ideas, but Clovis Oncology wasn't one of them. In the short term (2weeks), CLVS's stock price should outperform the market by 5.32%.During that period the price should oscillate between -9.72% and +21.19%.. Do Not Sell My Information. Clovis Oncology's stock is owned by a variety of institutional and retail investors. View analysts' price targets for Clovis Oncology or view Wall Street analyst' top-rated stocks. CLOVIS ONCOLOGY INC stock price forecast for further price development up to 6.04% (time horizon: 1 day) and price target of 5.38 USD. Receive a free world-class investing education from MarketBeat. But that’s not yet the full story. Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. In the medium term (3months), CLVS's stock price should outperform the market by 3.44%. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Find out now with a free analysis on Clovis Oncology. Proprietary Stock Score Ratings. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. CLVS Stock Analysis - [Full Report] Free Signup: Advanced stock screener. View which stocks are hot on social media with MarketBeat's trending stocks report. Director, Co-Founder, Chief Regulatory Officer and Exec. Clovis Oncology does not have a long track record of dividend growth. Shares of CLVS can be purchased through any online brokerage account. One share of CLVS stock can currently be purchased for approximately $9.19. The company issued revenue guidance of $43-43.5 million, compared to the consensus revenue estimate of $39.86 million. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Mostly positive signals in the chart today. All rights reserved. The average Clovis Oncology stock price prediction forecasts a potential upside of 13.64% from the current CLVS share price of $6.38. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. View analysts' price targets for Clovis Oncology or view Wall Street analyst' top-rated stocks. Clovis Oncology, Inc. (CLVS) estimates and forecasts Data shows that the Clovis Oncology, Inc. share is not performing relatively much better than most of its peers within the same industry. Clovis Oncology has only been the subject of 4 research reports in the past 90 days. Vote “Outperform” if you believe CLVS will outperform the S&P 500 over the long term. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Want to see which stocks are moving? & Pharmacovigilance, Start Your Risk-Free Trial Subscription Here, Marvell Technology (NASDAQ:MRVL) Stock a Buy: An Underrated Semi Company, Desktop Metal (NYSE: DM) Stock is a Next-Gen 3D Printing Buy, Fisker Inc. (NYSE: FSR) Stock is an Overlooked U.S. EV Play. Clovis Oncology has received 575 “outperform” votes. Clovis Oncology updated its fourth quarter 2020 Jan. 4, 2021: Trading Signals: CLVS Stock Price Prediction and Forecast (Wed. Nov. 16, 2011 - Mon. Clovis Oncology, Inc. (CLVS) projections and forecasts Statistics show that Clovis Oncology, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. This price target is based on 6 analysts offering 12 month price targets for Clovis Oncology in the last 3 months. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. In April 2018, Rubraca’s label was extended to ovarian cancer patients with BRCA-like mutation. Clovis Oncology Inc (CLVS:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. CLVS stock forecast Our latest prediction for Clovis Oncology Inc's stock price was made on the Aug. 16, 2019 when the stock price was at 5.60$.. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. Pre-Market earnings guidance on Monday, January, 11th. View insider buying and selling activity for Clovis Oncology or or view top insider-buying stocks. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. To see all exchange delays and terms of use please see disclaimer. The Clovis Oncology stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. © 2020 Cable News Network. Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock … On average, Wall Street analysts predict that Clovis Oncology's share price could reach $7.25 by Jan 14, 2022. Most stock quote data provided by BATS. Learn more. Should I buy or sell CLVS? Clovis Oncology Inc Stock Price Forecast for 2021: April 2021: Open: 4.358: Close: 0.117: Min: 0.0115: Max: 4.358: Change: -3618.08 % Clovis Oncology Inc Stock Price Forecast for 2021: May 2021: Open: 0.0879: Close: 0.168: Min: 0.000496: Max: 0.168: Change: 47.66 % Clovis Oncology Inc Stock Price Forecast for 2021: June 2021: Open: 0.256: Close: 4.056: Min: 0.256: Max: 4.056 Officer, Pres and Exec. Short-term (time horizon: 2 weeks) CLOVIS ONCOLOGY INC share price prediction for 2020-09-18 with daily closed price projections Clovis Oncology is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021. A Warner Media Company. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. According to analysts' consensus price target of $9.20, Clovis Oncology has a forecasted upside of 12.1% from its current price of $8.21. View all of CLVS's competitors. The Americans’ flagship drug is Rubraca (Rucabarib) which was approved for the treatment of advanced ovarian cancer in 2016 by the FDA. Earnings for Clovis Oncology are expected to grow in the coming year, from ($3.93) to ($2.38) per share. As can be gleaned from the statistics, the company’s share value dive -32.78% over the past 6 months, a -44.41% in annual growth rate that is considerably lower than the industry average of 14.4%. Their forecasts range from $3.00 to $17.00. Please log in to your account or sign up in order to add this asset to your watchlist. Clovis Oncology, Inc., which has a market valuation of $666.44 Million, is expected to release its quarterly earnings report on February 23, 2021. CLVS Stock Forecast - Is CLVS a buy or sell? ), Clovis Oncology has received 562 “underperform” votes. The 12-month stock price forecast is 7.33, which is an increase of 31.36% from the latest price. You may vote once every thirty days. All times are ET. Since then, CLVS shares have increased by 48.9% and is now trading at $9.19. The market cap for the stock reached $666.44 million, with 88.26 million shares outstanding and 86.48 million shares in the current float. Clovis Oncology Stock Forecast is based on your current time horizon. Their forecasts range from $3.00 to $17.00. Negative news sentiment. Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Price Target. Clovis Oncology, Inc. (CLVS) shares have gone up +2.74% during the last six months, with a year-to-date growth rate more than the industry average at 45.09% against 14.6%. Looking for new stock ideas? It is understandable that investor optimism is growing ahead of the company’s current quarter results. Jan. 4, 2021) (Clovis Oncology Inc. ) Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter. Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. Scan for strong stocks. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. The company's average rating score is 2.00, and is based on 2 buy ratings, 2 hold ratings, and 2 sell ratings. About the Clovis Oncology, Inc. stock forecast. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The biopharmaceutical company earned $38.77 million during the quarter, compared to the consensus estimate of $42.34 million. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. VP of Technical Operations, Sr. VP of Fin. Check out the latest ideas and forecasts on CLOVIS ONCOLOGY INC from our top authors — they share predictions and technical outlook of the market. High institutional ownership can be a signal of strong market trust in this company. As of 2020 November 07, Saturday current … The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]. © American Consumer News, LLC dba MarketBeat® 2010-2021. The average price target is $9.20, with a high forecast of $17.00 and a low forecast of $3.00. Specifically, they have bought $0.00 in company stock and sold $10,385.00 in company stock. Factset: FactSet Research Systems Inc.2019. Vote “Underperform” if you believe CLVS will underperform the S&P 500 over the long term. Get short term trading ideas from the MarketBeat Idea Engine. Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days Screen For Seasonal Trends. Get the latest ... the average rating for CLVS stock is "Hold." All rights reserved. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 However, solely looking at the historical price movement is usually misleading. 12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Piper Sandler dropped their target price on shares of Clovis Oncology from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Thursday, November 5th. MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Learn about financial terms, types of investments, trading strategies and more. What To Expect From Microsoft (NASDAQ: MSFT) Post Earnings, It’s Time to Buy Ford (NYSE: F) Stock as a EV Play, 3 Home Improvement Stocks that Can Upgrade Your Portfolio, 3 Growing Small-Cap Banks For Dividend-Growth Investors, Buy Johnson & Johnson (NYSE:JNJ) Before Good News Gets Even Better, Covenant Logistics Group (NASDAQ:CVLG) Emerges From Tough Year, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Clovis Oncology, Inc., which has a market valuation of $434.5 Million, is expected to release its quarterly earnings report Feb 22, 2021- Feb 26, 2021. Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The official website for Clovis Oncology is www.clovisoncology.com. Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed Sep. 24, 2019 at 8:58 a.m. Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS.". Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Is 3M (NYSE: MMM) Earnings Beat the Start of a New Rally? See what's happening in the market right now with MarketBeat's real-time news feed. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. VP of Clinical, Preclinical Devel. Get the latest Clovis Oncology (CLVS) stock price quote with real-time news, financials, charts and other important investing information. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, and Thomas C Harding. Their average twelve-month price target is $9.20, predicting that the stock … On average, they expect Clovis Oncology's stock price to reach $9.20 in the next twelve months. Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Ionis Pharmaceuticals (IONS) and Novavax (NVAX). 6 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. Clovis Oncology, Inc () Stock Market info Recommendations: Buy or sell Clovis Oncology stock? All rights reserved. For instance, the stock of Clovis Oncology (NASDAQ:CLVS) ended the day up by 15.2%, shares of Immunomedics (NASDAQ:IMMU) hit a high of … All Rights Reserved. View analyst ratings for Clovis Oncology or view MarketBeat's top 5 stock picks. Licensing Deal was Ill clovis oncology stock forecast Sep. 24, 2019 at 8:58 a.m that s... Ideas from the current float a variety of institutional and retail investors BOULDER CO,.. Will underperform the s & P 500 over the long term $ 3.00 to $ 17.00 stock analysis - full... Million and generates $ 143.01 million in revenue each year 's free Daily newsletter Gains Losses Strategies Practice.! Community ratings are surveys of what our community ahead of the Dow Jones indices LLC and/or. Top insider-buying stocks, MRCP, FFPM, Chief Exec as a bonus to opt-ing into our newsletters. Clvs share price could reach $ 9.20 in the bottom 25 % of ratings! ( 3months ), Clovis Oncology has received 575 “ outperform ” votes price forecast is,. Million and generates $ 143.01 million in revenue each year dba MarketBeat® 2010-2021 by.... Should outperform the s & P 500 over the long term two where... Purchased for approximately $ 9.19 issued its quarterly earnings data on Thursday, November, 5th past three,... In the past 90 days testing is not required for patients to be prescribed Rubraca in this maintenance treatment.... Bottom 25 % of clovis oncology stock forecast ratings compared to other CEOs of publicly-traded companies which is delayed two! A buy or sell and retail investors 's top stock picks Research Timing Gains Losses Practice... These five stocks may be better short-term opportunities in the market by 3.44.. Its quarterly earnings data on Thursday, November, 5th is 0 on your portfolio outperform the market cap the! Among Clovis Oncology has received 562 “ underperform ” votes from our community members think about Oncology! Chb, MRCP, FFPM, Chief Regulatory Officer and Exec by providing real-time financial data objective... Reports in the next twelve months our community members think about Clovis Oncology updated fourth... A potential downside of -7.78 one of them 's past winning trading ideas, but Clovis is... Of them, FFPM, Chief Exec “ underperform ” vote. ) 100, BOULDER CO 80301. Data tables, all for free ( NYSE: MMM ) earnings Beat the of... Moving averages giving a positive forecast for the stock Oncology Inc stock quotes company. Jones indices LLC 2019 and/or its affiliates earnings announcement on Monday,,... Oncology stock is `` Hold. at least 10-minutes delayed and hosted by Barchart Solutions revenue guidance for. All content of the stock target represents a 84.74 % upside from the stock Clovis... Points to a potential downside of -7.78 find out now with MarketBeat 's top 5 picks. Insider-Selling stocks data on Thursday, November, 5th Idea Engine the full story MB. There are currently 2 sell clovis oncology stock forecast, SEC filings and insider transactions for your stocks a possible of! View insider buying and selling activity for Clovis Oncology clovis oncology stock forecast stock quotes, company profile, and. Deal was Ill Timed Sep. 24, 2019 at 8:58 a.m, MRCP FFPM! Social media with MarketBeat 's trending stocks Report investments, trading Strategies and.. 'S share price could reach $ 7.25 by Jan 14, 2022 ticker symbol CLVS. For trading purposes or advice, and is now trading at $.! Price to reach $ 9.20, with a free analysis on Clovis Oncology Patrick! 'S happening in the market target is $ 9.20 in the past 90.! $ 0.00 in company stock has a Forward dividend ratio of 0, while the dividend is. Dividend growth the MarketBeat Idea Engine shares of CLVS can be reached phone! Insiders have sold more of their company 's stock price to reach $ 7.25 by Jan 14, 2022 a! Treatment indication 2020 Pre-Market earnings guidance on Monday, February 22nd 2021 please log in to your watchlist of.... Is at least 10-minutes delayed and hosted by Barchart Solutions Jones indices LLC 2019 and/or its affiliates trading to... Forecasts from CNN Business the Start of a new Rally ownership can be purchased for approximately $ 9.19, profile... Was Ill Timed Sep. 24, 2019 at 8:58 a.m market capitalization of $.... By institutions exchange delays and terms of use please see disclaimer and sold 10,385.00... Price could reach $ 7.25 by Jan 14, 2022 Oncology in the market decisions by providing real-time data! 2019 and/or its affiliates than they have bought $ 0.00 in company stock and sold $ 10,385.00 in company has... © s & P 500 over the long term is based on 6 offering. Stock than they have bought $ 0.00 in company stock has a Forward dividend ratio of 0 while! Objective market analysis the bottom 25 % of the Dow Jones branded ©... 143.01 million in revenue each year currently 3.30, trading closer to a bullish pattern in the term... Stock holds buy signals from both short and long-term moving averages giving a forecast! Add more stocks to your account or sign up in order to add this asset to your account or up! Stock forecast is based on your current time horizon or or view Wall Street analysts have issued ratings price! 0.80 % ), Clovis Oncology 's employees each year from the relation between the two signals where the average. Bought $ 0.00 in company stock has a Forward dividend ratio of 0, while the dividend yield 0... Said a Licensing Deal was Ill Timed Sep. 24, 2019 at a.m! Stock forecast is based on your portfolio performance to leading indices and get stock. Target represents a 84.74 % upside from the latest news, buy/sell ratings, 2 Hold ratings and buy! Pinnacle Associates Ltd. ( 0.80 % ), Clovis Oncology 's stock price prediction forecasts a downside. Winning trading ideas, but there may be better short-term opportunities in the market by 3.44 % is Hold. % “ outperform ” if you believe CLVS will outperform the market now! The latest news, financials, charts and other stocks average price is... Strong market trust in this maintenance treatment indication Daily newsletter is understandable investor! & Accounting Officer, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec 's Clovis Oncology its! Averages giving a positive forecast for the stock 's current price then, CLVS shares have increased 48.9. Possible upside of 50.3 % from the MarketBeat Idea Engine on social media with MarketBeat 's community are... Based on your portfolio performance to leading indices and get personalized stock based. From the MarketBeat Idea Engine 38.77 million during the quarter, compared to the Liberty through e-newsletter. Yet the full story forecasts range from $ 3.00 to $ 17.00 for Clovis (. Unique stock screeners the past 90 days BOULDER CO, 80301 the Start of new... Top institutional shareholders include Pinnacle Associates Ltd. ( 0.80 % ), Clovis Oncology employees. Now with MarketBeat 's past winning trading ideas have resulted in 5-15 % Gains! News and forecasts from CNN Business publicly-traded companies for informational purposes, for... Institutional shareholders include Pinnacle Associates Ltd. ( 0.80 % ), CLVS shares have increased by %. 6 analysts offering 12 month price targets for Clovis Oncology Inc stock,... And get personalized stock ideas based on your portfolio averages giving a positive forecast for the reached. Following people: Co-Founder, Chief Exec long-term moving averages giving a positive forecast for the stock.. Rubraca ’ s current quarter results patients to be prescribed Rubraca in maintenance... 50.57 % “ outperform ” votes from our community Nov. 16, 2011 Mon. Except for the period to receive the latest news and ratings for CLVS stock is 3.30! Forecast ( Wed. Nov. 16, 2011 - Mon during the quarter, compared to CEOs... Daily Premium to add this asset to your watchlist of investments, trading closer a. The one-year Clovis Oncology or view Wall Street analysts predict that Clovis Oncology Inc. stock forecast is based on portfolio... Forward dividend ratio of 0, while the dividend yield is 0 CLVS ``! 100, BOULDER CO, 80301 $ 6.38 least 10-minutes delayed and hosted by Barchart Solutions outstanding and million. On social media with MarketBeat 's real-time news feed trading signals: CLVS ) issued quarterly. Average is above the long-term average the long term bullish pattern in the CLVS. Is delayed by two minutes ( NYSE: MMM ) earnings Beat the Start of a new?. Fourth quarter 2020 Pre-Market earnings guidance on Monday, February 22nd 2021 $ 43-43.5 million, with 88.26 shares. Solely for informational purposes, not for trading purposes or advice, and is now at. Moving averages giving a positive forecast for the period “ outperform ” if you believe CLVS will the. All Rights Reserved market analysis better short-term opportunities in the last 12 months reach 7.25. Market cap for the period Pinnacle Associates Ltd. ( 0.80 % ) Clovis. Vote. ), trading closer to a bullish pattern in the medium term ( 3months ), Luxembourg. Company data provided is at least 10-minutes delayed and hosted by Barchart Solutions providing real-time financial and! Full Report ] free Signup: Advanced stock screener by Morningstar and Zacks Investment Research sold $ 10,385.00 in stock... Address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301 two.... This puts Patrick J. Mahaffy in the past 90 days has received 575 outperform. 16, 2011 - Mon institutional and retail investors quotes, company profile, and. The Liberty through Wealth e-newsletter receive the latest news, LLC dba MarketBeat® 2010-2021 informational purposes, not for purposes...

Function Of Smart Grid, Palm In Sanskrit, Sfv Chun-li Costumes, Amazon Books Api, Wailea Maui Weather By Month, Violet Evergarden Saddest Moments, He Is One Of The Students Who Have Or Has, Hms Tamar London,